JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib

Br J Haematol. 2025 Jan 15. doi: 10.1111/bjh.19979. Online ahead of print.

Andrea Ceccardi^{1

2}, Martina Dameri², Francesco Ravera^{1

2}, Nicolò Gilardi^{1

2}, Mario Stabile^{1

2

3}, Isabella Lombardo⁴, Davide Ceresa², Monica Colombo⁵, Tiziana Vigo⁶, Benedetta Cigolini^{1

2}, Giulia Rivoli⁷, Matteo Dragani⁷, Irene Solimano¹, Anna Garuti², Andrea Bellodi², Alberto Ballestrero^{1

2}, Lorenzo Ferrando², Gabriele Zoppoli^{1

2}

¹ Department of Internal Medicine and Medical Specialties (DiMI), Università di Genova, Genoa, Italy.
² IRCCS Policlinico San Martino, Genoa, Italy.
³ Institut Jules Bordet, Bruxelles, Belgium.
⁴ Beyond Pharma Ltd., Milan, Italy.
⁵ Molecular Pathology Unit, IRCCS Policlinico San Martino, Genoa, Italy.
⁶ Laboratory of Experimental Neuroscience, IRCCS Policlinico San Martino, Genoa, Italy.
⁷ Hematology and Cellular Therapy Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

No abstract available

Publication types